Topics

Articles

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Who Moved My Prescription?

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Obesity Treatment Zepbound Now Available in United States

Investigation notes a need for greater transparency in 340B program revenue and strengthened enforcement authority for the Health Resources and Services Administration. 

Examination of 340B Drug Pricing Shows Program is Beneficial to Patients, Costly to Manufacturers

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.

Major PBM to Offer Cost-Based Pricing Option for Prescription Medications 

Blue Fin Group exec speaks on his upcoming feature. 

Access Insights 2023: Bill Roth Talks 2024 Being the Year of "Who Moved my Prescription"

Videos

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener. 

Access Insights 2023: Bill Roth Provides an Overview of his Keynote Speech, Fight for the Dollar

Director of Berkeley Research Group explains changes to 340B moving forward. 

Access Insights 2023: Andrew Brownlee Discusses How the 340B Landscape Will Continue to Evolve Moving Forward

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing. 

Access Insights 2023: Andrew Brownlee Discusses How Manufacturers Calculate 340B Prices

Berkeley Research Group Director discusses what to expect at his upcoming session. 

Access Insights 2023: Andrew Brownlee Discusses Things to Expect in his "340B Lessons from the Field" Presentation

Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.

Market Access